Vertebral Augmentation: Is It Time to Get Past the Pain? A Consensus Statement from the Sardinia Spine and Stroke Congress

Joshua A. Hirsch 1, Chiara Zini 2, Giovanni Carlo Anselmetti 3, Francisco Ardura 4, Douglas Beall 5, Matteo Bellini 6, Allan Brook 7, Alessandro Cianfoni 8,9, Olivier Clerk-Lamalice 9, Bassem Georgy 10, Gianluca Maestretti 11, Luigi Manfré 12, Mario Muto 13, Orlando Ortiz 14, Luca Saba 15, Alexis Kelekis 16, Dimitrios K. Filippiadis 16,*,†, Stefano Marcia 17,‡ and Salvatore Masala 18,‡

1 Department of Radiology Massachusetts General Hospital, Harvard Medical School Boston, Boston, MA 02114, USA
2 UOC Radiologia Firenze 1, USL Toscana Centro, 50100 Firenze, Italy
3 Interventional Radiology Unit, European Institute of Oncology IEO Milan, 10060 Milan, Italy
4 Spine Unit, Orthopedics and Traumatology Department, University Clinical Hospital of Valladolid, 47000 Valladolid, Spain
5 Comprehensive Specialty Care, Oklahoma City, OK 7301, USA
6 UOC Neuroimaging, Neuroradiologia Clinica e Funzionale Dipartimento di Scienze Neurologiche e Motorie Azienda Ospedaliera Universitaria Senese, 53100 Siena, Italy
7 Department of Radiology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY 10467-2490, USA
8 Department of Interventional and Diagnostic Neuroradiology, Neurocenter of Southern Switzerland, EOC, 6900 Lugano, Switzerland
9 Beam Interventional & Diagnostic Imaging, Department of Interventional Pain Management, Calgary, AB 2500, Canada
10 Department of Radiology, University of California, San Diego, CA 92025, USA
11 Department of Orthopaedic Surgery and Traumatology, HFR Hôpital Cantonal, University of Fribourg, CH-1700 Fribourg, Switzerland
12 Minimal Invasive Spine Department of Neurosurgery, Istituto Oncologico del Mediterraneo IOM, 95029 Viagrande, Italy
13 UOC Neuroradiologia AO Cardarelli Naples Italy, 80131 Napoli, Italy
14 Department of Radiology, Jacobi Medical Center/Albert Einstein College of Medicine, Bronx, NY 11501, USA
15 Department of Radiology, Azienda Ospedaliero Universitaria (A.O.U.) di Cagliari, 09110 Cagliari, Italy
16 2nd Department of Radiology, University General Hospital “ATTIKON” Medical School, National and Kapodistrian University of Athens, 12462 Athens, Greece
17 UOC Radiologia SS, Trinità Hospital, 09121 Cagliari, Italy
18 Diagnostica per Immagini e Radiologia Interventistica, Università di Roma Tor Vergata, 00148 Roma, Italy
* Correspondence: dfilippiadis@yahoo.gr
† Current Address: Department of Interventional and Diagnostic Neuroradiology, Inselspital University Hospital of Bern, 3010 Bern, Switzerland.
‡ Current Address: 2nd Department of Radiology, University General Hospital “ATTIKON” Medical School, National and Kapodistrian University of Athens Addr., 1 Rimini Str., 12462 Athens, Greece.

Abstract: Vertebral augmentation has been used to treat painful vertebral compression fractures and metastatic lesions in millions of patients around the world. An international group of subject matter experts have considered the evidence, including but not limited to mortality. These considerations led them to ask whether it is appropriate to allow the subjective measure of pain to so dominate the clinical decision of whether to proceed with augmentation. The discussions that ensued are related below.

Keywords: pain; vertebroplasty; ablation; augmentation; kyphosis; target; future; treatment

In her classic song, Haven’t got time for the pain, Carly Simon famously finished by stating, “the time for the pain is over.” As it relates to vertebral compression fractures
(VCFs), the multidisciplinary group of subject matter experts serving as faculty at the Sardinian Spine and Stroke 2022 conference propose modifying Ms. Simon’s tagline in order to rethink the perseveration on pain palliation that has typified the approach towards VCFs [1]. Vertebral augmentation has changed the landscape for patients suffering from painful vertebral compression fractures [2]. What had previously been a disease lacking effective treatments beyond non-surgical management (NSM) could now reliably, and with low complication rates, get patients out of the hospital, with rapid mobilization and a return to normal function [3,4].

Radiologists were critical of the emergence of this then-nascent approach to treating VCFs [5]. For many radiologists, this may have been their first exposure to treating pain. Perhaps understandably, an orthodoxy began to develop and held the viewpoint that absent significant pain, vertebral augmentation should not be performed. There is a clear logic to this, as pain treatments should never be performed simply to address imaging findings. However, it might be possible that this approach is hindering advancement in the field and, more importantly, limiting appropriate access to the procedure. Pain assessments are inherently subjective, and the literature abounds in inconsistencies with respect to patient assessment, validated pain scales, patient follow-up methodologies, confounding sham treatments and placebo effects [6,7]. Re-focusing attention on the biomechanical effect of percutaneous augmentation allows one to utilize an objective platform to assess these interventions with reproducible, measurable outcomes. One can then show the efficacy of these procedures in terms of their impact on the functional spine unit, including the disc–endplate complex and facet joints, and on sagittal balance, with off-loading of the anterior vertebral column secondary to height restoration and prevention of further height loss of treated vertebrae.

The blinded trials that have followed patients for extended periods after randomization have convincingly demonstrated a preservation of sagittal height relative to sham patients from the same trials [8,9]. Traditionally, the preservation of vertebral height alone would not generally be considered by many practitioners significant enough to warrant the risk of intervention [10]. However, the faculty of the Sardinian conference wondered if this rationale is entirely appropriate. Anterior column fractures will, over time, often lead to hyperkyphosis, disc degeneration, facet osteoarthritis, spinal canal stenosis and other causes of chronic pain [11–13]. Early intervention or augmentation when the fracture is still able to be optimally reduced might stave off these undesirable secondary effects, such as reducing adjacent-level creep deformation [14]. Every patient experiences an informed consent prior to a procedure where the risks are detailed, but none of the faculty indicated that they mention the risk of acute or subacute fracture turning into a chronic condition prone to a segmental degenerative change often associated with pain if the vertebra is not treated.

Demonstrating the potentially misleading nature of retrospective case series, relatively early in the U.S. vertebral augmentation experience Uppin et al. concluded that augmentation was associated with an increased incidence of additional fractures [15]. This highly cited paper soon became a focal point for those who did not support/believe in augmentation despite the fact that when compared with non-surgical management, patients did much better with augmentation [16,17]. A few years later, various meta-analyses comparing augmentation to either conservative therapy or sham have demonstrated that adjacent level fractures following augmentation matches natural history [18–20]. While that literature is substantial in disproving the Uppin case series, the more recent SAKOS trial and other data suggests that subtypes of augmentation might have lower levels of adjacent level fractures than traditional vertebroplasty or kyphoplasty [21,22]. This would then imply that instrumented augmentation and implants other than polymethylmethacrylate might decrease adjacent level fracture rates to levels below that of the natural history of the disease. While there is no consensus that these studies are authoritative in making this aspirational point, if true, the rationale for an augmentation becomes ever stronger. Put differently, should a patient who has relatively modest pain be denied the potential
benefit of lowering the natural history of adjacent level fractures? Should that patient with modest pain be denied the potential benefit of a vertebra with at least partially restored morphology, ability to sustain axial load, and ultimately more physiological biomechanical function? Beyond that, questions can be raised on the role of prophylactic vertebroplasty though that is beyond the intended scope of this comment [23].

Cianfoni et al. have published multiple studies looking at the stent and screw-assisted internal fixation (SAIF) technique [24–28]. Utilizing this method, extremely complex osteoporotic and neoplastic fractures can be approached, stabilized, and anatomically corrected, confirming results from preliminary biomechanical studies. The alternative to SAIF in many of these vulnerable patients would be reconstructive open spine surgery. Cianfoni, as faculty of the Sardinian conference, noted that a common theme for these SAIF paper submissions is that reviewers typically insist the authors provide Visual Analog Score or Numeric Rating Score data. When one considers the numerous publications supporting pain relief utilizing traditional augmentation including multiple randomized control trials, it is reasonable to wonder what these small but extreme patient series would contribute to the understanding of how cementation impacts mechanical pain from fractures [29]. For the subgroup of these extreme SAIF patients, more relevant measures include how frequently patients avoided conventional surgery, the ability to obtain vertebral body reconstruction, correction of posterior wall encroachment, the degree of improvement in sagittal balance, and how safe and durable these procedures' biomechanical advantages are [30,31]. Nonetheless, the treatment of pain is so ingrained in the minds of augmentation practitioners, it becomes a dominant question for expert reviewers seemingly every time one of these papers is subjected to peer review. We claim that vertebral augmentation (VA) is superior to Non-Surgical Management (NSM). Additionally, concerning more complex fractures, where posterior tension band is injured and/or screws are needed, we claim that VA+Vertebral Posterior Fixation (VPF) is superior to classical gold standard stand-alone VPF. Even in many cases in which a double approach, i.e., anterior and posterior surgical approach of the spine, is performed, vertebral augmentation can play a role in avoiding the anterior approach and minimize comorbidities from the procedure, with better short-term clinical results, and similar clinical and radiological medium- and long-time results.

OPuS One was a landmark study looking at radiofrequency ablation (RFA) of spinal metastases [32]. Due to ethical considerations and provider/patient preference, trial participants could be treated with RFA alone, but the vast majority of patients underwent both RFA and cementation. This study is appropriately reported as very supportive of the techniques and has likely contributed to greater utilization of RFA in these types of patients. Indeed, the consensus opinion of the authors of this comment is that the increasing use of RFA in this cohort is good for the patients undergoing these procedures. Once again, however, the subject matter experts of the Sardinian conference are left to wonder if pain was the optimized measurement for this cohort. The authors of this report would argue that it was not. When one compares the results of the CAFÉ trial to OPuS One (i.e., cementation with and without RFA) it is difficult to conclude that pain control was improved by RFA [33,34]. When one considers the rationales for an ablative technique including procedural safety, local tumor control, debulking of disease or decreasing the potential for tumor spread, one can wonder about the value of studying pain as the primary endpoint [35,36]. Indeed, the potential benefit of these interventions in cancer patients with spine involvement, although previously understated, can be attributed to the prevention of spinal instability and spinal canal compromise. These are objective measurable endpoints which can be assessed at follow-up and have important biomechanical implications. A spinal instability score is obtained at the time of the patient’s clinical presentation; it seems intuitive that the score can be improved following these percutaneous interventions [37,38].

It is evident that vertebral fractures contribute to mortality and lower survival of patients; furthermore, hospitalization burden and cost of VCFs management has been shown to be higher than that of myocardial infarct, cerebrovascular accident or breast cancer [39,40]. The accepted threshold for complications related to vertebral augmentation
techniques is in the range 2.2–3.9\% for osteoporotic fractures [4]. The literature data clearly suggest that complications from performing vertebral augmentation are less than complications from not performing the procedure. A growing body of literature demonstrates improved mortality in patients undergoing vertebral augmentation as compared with patients treated with conservative therapy [41–43]. Ong et al. found a statistically significant difference comparing time matched periods before and after the equivocal 2009 NEJM studies, which the authors hypothesized might relate to a decrease in utilization of vertebral augmentation procedures [44,45]. This investigation was followed by a meta-analysis of sixteen studies that convincingly made this point [46]. Utilizing the same claims-based dataset, Ong, et al. then converted the survival probability data from this 10-year period into a number needed to treat analysis and found remarkably small numbers of patients that would need to be treated to lead to a difference in survivability [47]. The authors also speculated on the reasons for the improved mortality with rationales ranging from decreased opioid requirements, greater mobility, and sagittal balance preservation with Oxford Level 2a evidence supporting these mortality claims [46]. The rationale for the improved survival in patients treated with vertebral augmentation, while not completely certain, is likely multifactorial. What if sagittal balance preservation or improvement is a meaningful part of that claim? In a situation where augmentation provides a mortality benefit, is it appropriate to limit treatment to those with significant pain? [48]. Future research upon vertebral augmentation techniques could utilize more deliberate and objective methods with more extensive evaluation factors and the inclusion of more patients with different baselines who will be followed up for longer periods of time [49].

The three days in Cagliari raised many questions around a common theme. Augmentation has been reported in thousands of publications to be an effective treatment for painful vertebral compression fractures. In that clinical scenario, the literature largely believes it to be successful [50–52]. Emerging arguments support the use of vertebral augmentation for sagittal balance preservation and restoration. Perhaps that preservation plays an important role in the strong mortality benefit associated with augmentation. Cancer patients undergoing radiofrequency ablation are not necessarily evaluated in the way other ablative, e.g., radiation therapy occurs but rather as it relates to pain relief. Cianfoni describes techniques that resolve the issue of undertreatment of the anterior column alone via augmentation with multicolumn support vs. overtreatment in these vulnerable patients. While patients treated with SAIF would typically be treated surgically where pain relief would be a secondary rationale, reviews of these submissions often focus on that as a primary component. Thirty-five years after the first vertebroplasty, it may be time to target something other than pain [53]. The knowledge accumulated during this period suggests that we should focus on some other aspects of vertebral compression fractures: prevention of progressive collapse, chronic pain, adjacent level fractures; anatomical restoration of the vertebrae and sagittal balance restoration; correction of kyphotic deformity. The author’s consensus is that broadening our treatment focus will improve patients’ clinical results. Perhaps, to play on Carly Simon’s famous lyrics, in some patients, we have reached a point where the “need for the pain” palliation should be considered along with the other demonstrable benefits of vertebral augmentation.

**Author Contributions:** Conceptualization, D.K.F., J.A.H., S.M. (Salvarore Masala) and S.M. (Stefano Marcia); methodology, J.A.H. and C.Z.; validation, J.A.H., G.C.A., F.A., D.B., M.B., A.B., A.C., O.C.-L., D.K.F., G.M., B.G., L.M., S.M. (Salvarore Masala) and S.M. (Stefano Marcia), M.M., O.O., L.S., A.K. and C.Z.; writing—original draft preparation, J.A.H., G.C.A., F.A., B.G., D.B., M.B., A.B., A.C., O.C.-L., D.K.F., G.M., L.M., S.M. (Salvarore Masala) and S.M. (Stefano Marcia), M.M., O.O., L.S., A.K. and C.Z.; writing—review and editing, J.A.H., C.Z., S.M. (Salvarore Masala) and S.M. (Stefano Marcia); project administration, J.A.H.; J.A.H.: Consultant Medtronic, Spine Biopharma, Persica, VIZ AI, Relievant. DMC chair: STEM study. All authors have read and agreed to the published version of the manuscript.

**Funding:** This work was in part supported by a grant from the Neiman Health Policy Institute.
Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Conflicts of Interest: The authors, other than below, declare no conflict of interest related to this work.

References
1. Simon, C. Haven't Got Time for the Pain; Track 11; Hotcakes, Elektra Records: New York, NY, USA, 1974.
2. Jensen, M.E.; Evans, A.J.; Mathis, J.M.; Callmes, D.F.; Cloft, H.J.; Dion, J.E. Percutaneous polymethylmethacrylate vertebroplasty in the treatment of osteoporotic vertebral body compression fractures: Technical aspects. AJNR Am. J. Neuroradiol. 1997, 18, 1897–1904.
3. Barr, J.D.; Jensen, M.E.; Hirsch, J.A.; McGraw, J.K.; Barr, R.M.; Brook, A.L.; Society of Neurointerventional Surgery. Position statement on percutaneous vertebral augmentation: A consensus statement developed by the Society of Interventional Radiology (SIR), American Association of Neurological Surgeons (AANS) and the Congress of Neurological Surgeons (CNS), American College of Radiology (ACR), American Society of Neuroradiology (ASNR), American Society of Spine Radiology (ASSR), Canadian Interventional Radiology Association (CIRA), and the Society of NeuroInterventional Surgery (SNIS) Practice Guideline. J. Vasc. Interv. Radiol. 2014, 25, 171–181. [CrossRef]
4. Tsoumakidou, G.; Too, C.W.; Koch, G.; Caudrelie, J.; Cazzato, R.L.; Gannon, J.; Gangi, A. CIRSE Guidelines on Percutaneous Vertebral Augmentation. Cardiovasc. Intervent. Radiol. 2017, 40, 331–342. [CrossRef] [PubMed]
5. Anselmetti, G.C.; Manca, A.; Hirsch, J.; Montemurro, F.; Isia, G.; Osella, G.; Regge, D. Percutaneous vertebroplasty in osteoporotic patients: An institutional experience of 1,634 patients with long-term follow-up. J. Vasc. Interv. Radiol. 2011, 22, 1714–1720. [CrossRef] [PubMed]
6. Fillingim, R.B. Individual differences in pain: Understanding the mosaic that makes pain personal. Pain 2017, 158 (Suppl. 1), S11–S18. [CrossRef] [PubMed]
7. Manchikanti, L.; Boswell, M.V.; Kaye, A.D.; Helm, I.S.; Hirsch, J.A. Therapeutic Role of Placebo: Evolution of a New Paradigm in Understanding Research and Clinical Practice. Pain Physician 2017, 20, 363–386.
8. Clark, W.; Bird, P.; Gonski, P. Safety and efficacy of vertebroplasty for acute painful osteoporotic fractures (VAPOUR): A multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2016, 388, 1408–1416. [CrossRef]
9. Firanescu, C.E.; de Vries, J.; Lodder, P.; Venmans, A.; Schoemaker, M.C.; Smeet, A.J.; Lohle, P.N. Vertebral fracture and kyphoplasty versus sham procedure for painful acute osteoporotic vertebral compression fractures (VERTOS IV): Randomised sham controlled clinical trial. BMJ 2018, 361, k1551. [CrossRef]
10. Hirsch, J.A.; Beall, D.P.; Chambers, M.R. Management of vertebral fragility fractures: A clinical care pathway developed by a multispecialty panel using the RAND/UCLA Appropriateness Method. Spine J. 2018, 18, 2152–2161. [CrossRef] [PubMed]
11. Lunt, M.; O’Neill, T.W.; Felsenberg, D.; Reeve, J.; Kanis, J.A.; Cooper, C.; Silman, A.J. European Prospective Osteoporosis Study Group Characteristics of a prevalent vertebral deformity predict subsequent vertebral fracture: Results from the European Prospective Osteoporosis Study (EPOS). Bone 2003, 33, 505–513. [CrossRef]
12. National Institutes of Health. Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy, Osteoporosis prevention, diagnosis, and therapy. JAMA 2001, 285, 785–795. [CrossRef]
13. Cauley, J.A.; Thompson, D.E.; Ensrud, K.C.; Scott, J.C.; Black, D. Risk of mortality following clinical fractures. Osteoporos. Int. 2000, 11, 556–561. [CrossRef]
14. Luo, J.; Annesley-Williams, D.J.; Adams, M.A.; Dolan, P. How are adjacent spinal levels affected by vertebral fracture and by vertebroplasty? A biomechanical study on cadaveric spines. Spine J. 2017, 17, 863–874. [CrossRef] [PubMed]
15. Uppin, A.A.; Hirsch, J.A.; Centenera, L.V.; Pfiefer, B.A.; Pazianos, A.G.; Choi, I.S. Occurrence of new vertebral body fracture after percutaneous vertebroplasty in patients with osteoporosis. Radiology 2003, 226, 119–124. [CrossRef] [PubMed]
16. Klazen, C.A.; Lohle, P.N.; De Vries, J.; Jansen, F.H.; Tielbeek, A.V.; Blonk, M.C.; Willem, P.T.M. Vertebral fracture and kyphoplasty compared with non-surgical care for vertebral compression fracture (FREE): A randomised controlled trial. Lancet 2010, 376, 1085–1092. [CrossRef]
17. Wardlaw, D.; Cummings, S.R.; Van Meirhaeghe, J.; Bastian, L.; Tillman, J.B.; Ranstam, J.; Boonen, S. Efficacy and safety of balloon kyphoplasty compared with non-surgical care for acute osteoporotic vertebral compression fracture (FREE): A randomised controlled trial. Lancet 2009, 373, 1016–1024. [CrossRef]
18. Xiao, H.; Yang, J.; Feng, X.; Chen, P.; Li, Y.; Huang, C.; Chen, H. Comparing complications of vertebroplasty and kyphoplasty for treating osteoporotic vertebral compression fractures: A meta-analysis of the randomized and non-randomized controlled studies. Eur. J. Orthop. Surg. Traumatol. 2015, 25 (Suppl. 1), S77–S85. [CrossRef]
19. Papapanastassiou, I.D.; Phillips, F.M.; Van Meirhaeghe, J.; Berenson, J.R.; Andersson, G.B.; Chung, G.; Vrionis, F.D. Comparing effects of kyphoplasty, vertebroplasty, and non-surgical management in a systematic review of randomized and non-randomized controlled studies. Eur. Spine J. 2012, 21, 1826–1843. [CrossRef]
20. Beall, D.P.; Lorio, M.P.; Yun, B.N.; Runa, M.J.; Ong, K.L.; Warner, C.B. Review of Vertebral Augmentation: An Updated Meta-analysis of the Effectiveness. J. Spine Surg. 2018, 12, 295–321. [CrossRef] [PubMed]
21. Noriega, D.; Marcia, S.; Theumann, N.; Blondel, B.; Simon, A.; Hassel, F.; Pflugmacher, R. A prospective, international, randomized, noninferiority study comparing an implantable titanium vertebral augmentation device versus balloon kyphoplasty in the reduction of vertebral compression fractures (SAKOS study). *Spine J.* 2019, 19, 1782–1795. [CrossRef]

22. Bae, H.; Hatten, H.P., Jr.; Linovitz, R.; Tahernia, A.D.; Schaufele, M.K.; McColm, V.; Persenaire, M. A Prospective Randomized FDA-IIE Trial Comparing Cortoss to PMMA for Vertebroplasty: A Comparative Effectiveness Research Study with 24-Months Follow-Up. *Spine* 2012, 37, 544–550. [CrossRef] [PubMed]

23. Chen, Z.; Song, C.; Lin, H.; Sun, J.; Weng, L. Does prophylactic vertebral augmentation reduce the refracture rate in osteoporotic vertebral fracture patients: A meta-analysis. *Eur. Spine J.* 2021, 30, 2691–2697. [CrossRef]

24. Cianfoni, A.; Delfanti, R.L.; Isalberti, M.; Scarone, P.; Koetsier, E.; Bonaldi, G.; Pileggi, M. Minimally Invasive Stent Screw-Assisted Internal Fixation Technique Corrects Kyphosis in Osteoporotic Vertebral Fractures with Severe Collapse: A Pilot “Vertebra Plana” Series. *AJNR Am. J. Neuroradiol.* 2022, 43, 776–783. [CrossRef] [PubMed]

25. Distefano, D.; Scarone, P.; Isalberti, M.; La Barbera, L.; Villa, T.; Bonaldi, G.; Cianfoni, A. The ‘armed concrete’ approach: Stent-screw-assisted internal fixation (SAIF) reconstructs and internally fixates the most severe osteoporotic vertebral fractures. *J. Neurointerv. Surg.* 2021, 13, 63–68. [CrossRef] [PubMed]

26. Cianfoni, A.; Distefano, D.; Scarone, P.; Espe, G.A.; Espeli, V.; La Barbera, L.; Hirsch, J.A. Stent-screw-assisted internal fixation (SAIF): Clinical report of a novel approach to stabilizing and internally fixating vertebral destroyed by malignancy. *J. Neurosurg. Spine* 2019, 20, 1–12. [CrossRef] [PubMed]

27. Cianfoni, A.; Distefano, D.; Isalberti, M.; Reinert, M.; Scarone, P.; Kuhlen, D.; Bonaldi, G. Stent-screw-assisted internal fixation: The SAIF technique to augment severe osteoporotic and neoplastic vertebral body fractures. *J. Neurointerv. Surg.* 2019, 11, 603–609. [CrossRef]

28. Cornelis, F.H.; Joly, Q.; Nouri-Neuville, M.; Ben-Ammar, M.; Kastler, B.; Kastler, A.; Amoretti, N.; Hauger, O. Innovative Spine Implants for Improved Augmentation and Stability in Neoplastic Vertebral Compression Fracture. *Medicina* 2019, 55, 426. [CrossRef]

29. Halvachizadeh, S.; Stalder, A.L.; Bellut, D.; Hoppe, S.; Rossbach, P.; Cianfoni, A.; Pape, H.C. Systematic Review and Meta-Analysis of 3 Treatment Arms for Vertebral Compression Fractures: A Comparison of Improvement in Pain, Adjacent-Level Fractures, and Quality of Life Between Vertebroplasty, Kyphoplasty, and Nonoperative Management. *BJR Rev.* 2021, 9, e21. [CrossRef]

30. Cianfoni, A.; Distefano, D.; Pravatà, E.; Espeli, V.; Espe, G.; Mordasini, P.; Bonaldi, G. Vertebral body stent augmentation to reconstruct the anterior column in neoplastic extreme osteolysis. *J. Neurointerv. Surg.* 2019, 11, 313–318. [CrossRef]

31. Venier, A.; Roccatagliata, L.; Isalberti, M.; Scarone, P.; Kuhlen, D.E.; Reinert, M.; Cianfoni, A. Armed Kyphoplasty: An Indirect Central Canal Decompression Technique in Burst Fractures. *AJNR Am. J. Neuroradiol.* 2019, 40, 1965–1972. [CrossRef]

32. Levy, J.; Hopkins, T.; Morris, J.; Tran, N.D.; David, E.; Massari, F.; Bagla, S. Radiofrequency Ablation for the Palliative Treatment of Bone Metastases: Outcomes from the Multicenter OsteoCool Tumor Ablation Post-Market Study (OPuS One Study) in 100 Patients. *Vasc. Interv. Radiol.* 2020, 31, 1745–1752. [CrossRef] [PubMed]

33. Berenson, J.; Pflugmacher, R.; Jarzem, P.; Zonder, J.; Schechtman, K.; Tillman, J.B.; Cancer Patient Fracture Evaluation (CAFE) Investigators. Cancer Patient Fracture Evaluation (CAFE) Investigators. Balloon kyphoplasty versus non-surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: A multicentre, randomised controlled trial. *Lancet Oncol.* 2011, 12, 225–235. [CrossRef]

34. Anselmetti, G.C.; Manca, A.; Montemurro, F.; Hirsch, J.; Chiarà, G.; Grignani, G.; Regge, D. Percutaneous vertebroplasty in multiple myeloma: Prospective follow-up in 106 consecutive patients. *Cardiovasc. Intervent. Radiol.* 2012, 35, 139–145. [CrossRef]

35. Jha, R.M.; Hirsch, A.E.; Yoo, A.J.; Ozonoff, A.; Grownwey, M.; Hirsch, J.A. Palliation of compression fractures in cancer patients by vertebral augmentation: A retrospective analysis. *J. Neurointerv. Surg.* 2010, 2, 221–228. [CrossRef] [PubMed]

36. Cazzato, R.L.; Arrigoni, F.; Boatta, E.; Bruno, F.; Chiang, J.B.; Garnon, J.; Barile, A. Percutaneous management of bone metastases: State of the art, interventional strategies and joint position statement of the Italian College of MSK Radiology (ICoMSKR) and the Italian College of Interventional Radiology (ICIR). *Radiol. Med.* 2019, 124, 34–49. [CrossRef]

37. Fisher, C.G.; Versteeg, A.L.; Schouten, R.; Boriani, S.; Varga, P.P.; Rhines, L.D.; Gokaslan, Z.L. Reliability of the spinal instability neoplastic scale among radiologists: An assessment of instability secondary to spinal metastases. *Am. J. Roentgenol.* 2014, 203, 869–874. [CrossRef]

38. Tomasian, A.; Jennings, J.W. Percutaneous Minimally Invasive Thermal Ablation of Osseous Metastases: Evidence-Based Practice Guidelines. *AJR Am. J. Roentgenol.* 2020, 215, 502–510. [CrossRef]

39. Singer, A.; Exuzides, A.; Spangler, L.; O’Malley, C.; Colby, C.; Johnston, K.; Agooda, I.; Baker, J.; Kagan, R. Burden of illness for osteoporotic fractures compared with other serious diseases among postmenopausal women in the United States. *Mayo Clin. Proc.* 2015, 90, 53–62. [CrossRef]

40. Lau, E.; Ong, K.; Kurtz, S.; Schmier, J.; Edidin, A. Mortality following the diagnosis of a vertebral compression fracture in the Medicare population. *J. Bone Joint Surg. Am.* 2008, 90, 1479–1486. [CrossRef]

41. Edidin, A.A.; Ong, K.L.; Lau, E.; Kurtz, S.M. Morbidity and Mortality after Vertebral Fractures: Comparison of Vertebral Augmentation and Nonoperative Management in the Medicare Population. *Spine* 2015, 40, 1228–1241. [CrossRef]
42. Chen, A.T.; Cohen, D.B.; Skolasky, R.L. Impact of nonoperative treatment, vertebroplasty, and kyphoplasty on survival and morbidity after vertebral compression fracture in the medicare population. *J. Bone Joint Surg. Am.* 2013, 95, 1729–1736. [CrossRef] [PubMed]

43. Lange, A.; Kasperk, C.; Alvares, L.; Sauermann, S.; Braun, S. Survival and cost comparison of kyphoplasty and percutaneous vertebroplasty using German claims data. *Spine* 2014, 39, 318–326. [CrossRef] [PubMed]

44. Hirsch, J.A.; Chandra, R.V.; Pampati, V.; Barr, J.D.; Brook, A.L.; Manchikanti, L. Analysis of vertebral augmentation practice patterns: A 2016 update. *Neuromicrosurg. Surg.* 2016, 8, 1299–1304. [CrossRef] [PubMed]

45. Ong, T.; Sahota, O.; Gladman, J.R.F. The Nottingham Spinal Health (NoSH) Study: A cohort study of patients hospitalised with vertebral fragility fractures. *Osteoporos. Int.* 2020, 31, 363–370. [CrossRef] [PubMed]

46. Hinde, K.; Maingard, J.; Hirsch, J.A.; Phan, K.; Asadi, H.; Chandra, R.V. Mortality Outcomes of Vertebral Augmentation (Vertebroplasty and/or Balloon Kyphoplasty) for Osteoporotic Vertebral Compression Fractures: A Systematic Review and Meta-Analysis. *Radiology* 2020, 295, 96–103. [CrossRef] [PubMed]

47. Hirsch, J.A.; Chandra, R.V.; Carter, N.S.; Beall, D.; Frohbergh, M.; Ong, K. Number Needed to Treat with Vertebral Augmentation to Save a Life. *Am. J. Neuroradiol.* 2020, 41, 178–182. [CrossRef]

48. Yang, H.L.; Zhao, L.; Liu, J.; Sanford, C.G., Jr.; Chen, L.; Tang, T.; Ebraheim, N.A. Changes of pulmonary function for patients with osteoporotic vertebral compression fractures after kyphoplasty. *J. Spinal Disord. Tech.* 2007, 20, 221–225. [CrossRef]

49. Wang, S.; Zheng, L.; Ma, J.X.; Wang, H.; Sun, S.T.; Zhang, B.H.; Guo, X.L.; Xiang, L.B.; Chen, Y. Analysis of the most influential publications on vertebral augmentation for treating osteoporotic vertebral compression fracture: A review. *Medicine* 2022, 101, e30023. [CrossRef]

50. Anselmetti, G.C.; Bernard, J.; Blattert, T.; Fagan, D.; Fransen, H.; Fransen, P.; Kasperk, C. Criteria for the appropriate treatment of osteoporotic vertebral compression fractures. *Pain Physician* 2013, 16, E519–E530. [CrossRef]

51. Fachklinik, O.; Schwarzach, S.; Beaulieu, C.G.; Stoeveelaar, H.; Belgium, L. Treatment of Osteoporotic Vertebral Compression Fractures: Applicability of Appropriateness Criteria in Clinical Practice. *Pain Physician* 2016, 19, E113–E120.

52. Filippiadis, D.K.; Marcia, S.; Masala, S.; Deschamps, F.; Kelekis, A. Percutaneous Vertebroplasty and Kyphoplasty: Current Status, New Developments and Old Controversies. *Cardiovasc. Intervent. Radiol.* 2017, 40, 1815–1823. [CrossRef] [PubMed]

53. Galibert, P.; Deramond, H.; Rosat, P.; Le Gars, D. Note préliminaire sur le traitement des angiomes vertébraux par vertébroplastie acrylique percutanée [Preliminary note on the treatment of vertebral angioma by percutaneous acrylic vertebroplasty]. *Neurochirurgie* 1987, 33, 166–168. [PubMed]